Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.43 |
| ▸ | CFD | P00746 | 2/20 | 0.43 |
| ▸ | TPSB2 | P20231 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23655308 | 0.89 | AGXT (0.50) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL28893947 | 0.88 | SLC6A2 (0.56) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL16189246 | 0.83 | ATM (0.39) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL16189455 | 0.83 | MAPT (0.44) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL17887234 | 0.82 | ACP3 (0.51) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL3173784 | 0.82 | MAP4K4 (0.51) | F11CFDTPSB2 | |
| SCHEMBL468022 | 0.82 | EPHX1 (0.61) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL272604 | 0.82 | EPHX1 (0.61) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL3451169 | 0.82 | EPHX1 (0.61) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL16189081 | 0.81 | ATM (0.40) | TAAR1SLC6A2MAOASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841504-B1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1841504-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006076575-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | TAAR1 3999/4885SLC6A2 3866/4885MAOA 339/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | TAAR1 3999/4885SLC6A2 3866/4885MAOA 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.